Vemurafenib for BRAF V600‐mutant Erdheim–Chester disease presenting with bilateral orbital involvement

Abstract

Abstract ECD is considered to have rapid progression and poor prognosis. Studies have shown that vemurafenib is effective for ECD patients with orbital involvement, but not for ECD with multiple organs. The refinement of treatment approaches and the increased awareness of ECD have led to a dramatic improvement in prognosis.

Keywords

• BRAFV600E mutation
• Erdheim–Chester disease
• targeted therapy